Identification | Back Directory | [Name]
3,4-bis(2-Methoxyethoxy)benzaldehyde | [CAS]
80407-64-3 | [Synonyms]
Erlotinib Impurity 60 3,4-bis(2-Methoxyethoxy)benzaldehyde Benzaldehyde, 3,4-bis(2-methoxyethoxy)- | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C13H18O5 | [MDL Number]
MFCD25562935 | [MOL File]
80407-64-3.mol | [Molecular Weight]
254.28 |
Chemical Properties | Back Directory | [Boiling point ]
380.1±42.0 °C(Predicted) | [density ]
1.115±0.06 g/cm3(Predicted) | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C |
Hazard Information | Back Directory | [Synthesis]
The general procedure for the synthesis of 3,4-bis(2-methoxyethoxy)benzaldehyde from 2-chloroethyl methyl ether and 3,4-dihydroxybenzaldehyde: 121 g (1 eq.) of 3,4-dihydroxybenzaldehyde was dissolved in 1200 ml of dimethylformamide (DMF) and stirred until a clarified solution formed; 323 g (4 eq.) of 2-chloroethyl methyl ether, 944 g (8 eq.) of anhydrous potassium carbonate, and 23.6 g of tetrabutyl ammonium bromide were added in turn. ) anhydrous potassium carbonate and 23.6 g of tetrabutyl ammonium bromide; the reaction system was purged with nitrogen for three times, and then the reaction mixture was heated to 105?110°C under nitrogen protection, and the reaction was carried out for 13?14 h. After the reaction was completed, the reaction mixture was filtered, and the filtrate cake was rinsed with dichloromethane (DCM) until the filtrate was colorless; the filtrates were combined, and the reaction mixture was concentrated under reduced pressure until no fractions were evaporated; the residue was added with DCM and cooled to room temperature. DCM, cooled to room temperature, washed sequentially with 3N potassium hydroxide solution, water and brine, the organic phase was dried with anhydrous sodium sulfate, and concentrated under reduced pressure to 45 ℃ to obtain 210 g of the oily product 3,4-bis(2-methoxyethoxy)benzaldehyde in 96.4% yield. | [References]
[1] Patent: CN105566233, 2016, A. Location in patent: Paragraph 0015; 0052 [2] Journal of Medicinal Chemistry, 1982, vol. 25, # 4, p. 435 - 440 [3] Patent: US2012/184548, 2012, A1. Location in patent: Page/Page column 23; 24 |
|
Company Name: |
BePharm Ltd
|
Tel: |
400-685-9117 |
Website: |
www.bepharm.com |
|